

---

**SUBJECT:** Infant and High Risk Children RSV Program – Fall/Winter 2024/2025  
**Date:** October 9, 2024  
**Pages:** 2  
**To:** Physicians, Hospitals  
**From:** Dr. Matthew Tenenbaum, Associate Medical Officer of Health

---

**Publicly-funded RSV immunoglobulin (nirsevimab/Beyfortus) is now available to order for your patients through the [WDG Public Health Vaccine Portal](#). Please refer to the [RSV Immunization Physician Advisory](#) (August 1, 2024) for additional details .**

Nirsevimab (Beyfortus) is a recombinant monoclonal antibody that protects against RSV-associated lower respiratory tract disease.<sup>1</sup> It is recommended for:

- All children born during the 2024-25 RSV season
- All children born in 2024 prior to the RSV season
- Children up to 24 months of age with any of:
  - Chronic lung disease of prematurity, including bronchopulmonary dysplasia
  - Hemodynamically significant congenital heart disease
  - Severe immunodeficiency
  - Down Syndrome / Trisomy 21
  - Cystic fibrosis with respiratory involvement and/or growth delay
  - Neuromuscular disease impairing clearing of respiratory secretions
  - Severe congenital airway anomalies impairing clearing of respiratory secretions

These groups are eligible for publicly funded doses which can now be ordered from WDGPH.

## About the Immunoglobulin Product

Beyfortus is administered as a single IM dose, just like a vaccine. It can be co-administered with routine childhood vaccines (incl. 2/4/6-month vaccines) or flu/COVID vaccines. **Please consider using well-child visits or other opportunities this fall/winter to offer Beyfortus to eligible patients.**

Beyfortus is available in both 50mg and 100mg prefilled syringes; please note that the recommended dose depends on the age and weight of the child according to the table below.

Pregnant individuals (32-36 weeks gestational age) may choose to receive RSVpreF (Abrysvo) vaccine, which provides protection to the infant through transplacental antibody transfer. In these scenarios, Beyfortus is generally not indicated for the infant. Infants who are high risk (per provincial guidance) should receive Beyfortus even if Abrysvo was administered in pregnancy.<sup>3</sup>

**Infant Immunoglobulin RSV Products**

<b>Manufacturer</b>	<b>Sanofi</b> Beyfortus™
<b>Date of Authorization</b>	April 19, 2023
<b>Type of Immunizing Agent</b>	Passive immunizing agent (human monoclonal antibody)
<b>Indication</b>	Prevention of RSV lower respiratory tract disease in: <ul style="list-style-type: none"> <li>• Infants born in 2024 prior to the RSV season</li> <li>• Infants born during the 2024/25 RSV season</li> <li>• Children up to 24 months of age at high risk of RSV disease</li> </ul>
<b>Dosage</b>	First RSV Season (i.e. born Jan 2024 or later) <ul style="list-style-type: none"> <li>• &lt; 5kg: 50 mg in 0.5 mL</li> <li>• ≥ 5 kg: 100 mg in 1.0 mL</li> </ul> Second RSV Season (for groups at high-risk) <ul style="list-style-type: none"> <li>• 200 mg (2 x 1 mL injections)</li> </ul>
<b>Route of Administration</b>	Intramuscular
<b>Number of Doses</b>	One dose
<b>Storage</b>	Stored at 2-8°C May be kept at 8-25°C for up to 8 hours before discarding

**Ordering Publicly Funded Vaccine**

RSV Monoclonal Antibody Beyfortus™ is now available to order. Please use the [WDG Public Health Vaccine Portal](#) OR [visit our website](#) to complete a vaccine order form and fax to 519-823-4903.

**Patient and Provider Resources**

Please refer patients/families to these additional resources about RSV immunization, as appropriate:

- [Fact Sheet for Parents and Expectant Parents](#) (PCMCH) [available in multiple languages]
- [RSV Videos](#) (Immunize Canada)
- General information about the [RSV Prevention Program](#) (Ontario Ministry of Health)
- [‘Knowing RSV’ website](#) (Sanofi)

Additionally, the following RSV resources are intended for health care providers:

- [Fact Sheet for Health Care Providers](#) (PCMCH)
- [Guidance for Health Care Providers – Beyfortus](#) (Ontario Ministry of Health)
- [RSV Vaccines: Canadian Immunization Guide](#) (NACI)
- [2024-2025 RSV Prevention Program Tool](#) (Centre for Effective Practice)
- [RSV: What you need to know](#) (CPHA) [webinar]
- [Product Monograph – Beyfortus](#)

## References

1. AstraZeneca Canada Inc. BEYFORTUS™ Product Monograph [Internet]. Toronto: AstraZeneca Canada Inc.; 2023. Available at: [https://pdf.hres.ca/dpd\\_pm/00070439.PDF](https://pdf.hres.ca/dpd_pm/00070439.PDF)
2. Public Health Agency of Canada. Respiratory syncytial virus (RSV): Canadian Immunization Guide. [Internet]. Ottawa (ON): Government of Canada; 2024 June. Available at: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html>
3. Ministry of Health. Infant and High-Risk RSV Prevention Program-Guidance for Health Care Providers-Niresvimab (Beyfortus™). <https://www.ontario.ca/files/2024-08/moh-infant-high-risk-children-rsv-beyfortus-guidance-hcp-en-2024-08-28.pdf>

## For more information, please contact:

Name/Title: Karen Mulvey, Manager, Vaccine Preventable Disease Program  
Email: [Karen.mulvey@wdgpublichealth.ca](mailto:Karen.mulvey@wdgpublichealth.ca)  
Website: [www.wdgpublichealth.ca](http://www.wdgpublichealth.ca)